How should we image liver hemangioma?

To the Editor: I read with interest the case report of liver hemangioma by S. Zinkirkeser in the last issue of Hell J Nucl Med, 9: 109-110 [1]. I think that some important points should be considered about this case report: The authors report that planar liver scintigraphy with technetium-99m-red blood cells (99mTc-RBC) was false negative due to shine through of the right kidney [1]. The single photon emission tomography (SPET) images provided by the authors clearly show that the lesion is in the superior and posterior portion of the right lobe of the liver, superior to the right kidney and at the level of the spleen. Surprisingly the planar 99mTc-RBC image which is shown in that case report is in an anterior view. The authors indicate that ultrasonography showed a 4.7 cm solid mass in the right lateral side of the liver while the SPET images showed that the lesion is in the posterior and medial portion of the right lobe of the liver. So it seems that the false negative finding of the planar liver scintigraphy in the case report is due to bad technique (acquiring anterior rather than posterior planar view) and not due to shine through of the right kidney.

It should be noticed that accurate imaging of liver hemangioma is highly dependent on the location of the hemangioma in the liver. Some authors prefer to perform ultrasonography before the 99mTc-RBC scan to determine the location of the lesion for best view imaging. [2] SPET imaging significantly increases the sensitivity of detection of hemangioma compared to delayed planar imaging. [3] It is also reported that even the dynamic three-view display of SPET slices, is superior to the conventional static SPET presentations. [4] So it is not surprising that hemangioma located in the posterior portion of the right lobe of the liver is not seen in the anterior projection due to attenuation of the photons by the overlaying liver tissue [2]. The purpose of liver imaging for the detection of a hemangioma is to find a RBC avid, space occupying lesion and for that multiple views should be acquired. In our experience, hemangiomas located in the left lobe or in the anterior portion of the right lobe are best seen in the anterior view and hemangiomas located in the posterior part of the right lobe are best seen in the posterior view while small hemangiomas in the central portion of the liver are not usually seen in the planar images and SPET imaging is necessary to identify them.

We usually image liver in multiple planar views and if a suspected hemangioma is not seen, SPET imaging is done in the same session. Repeating imaging after a second dose of radioisotope is the second question in this case report. Furthermore, as hemangioma is well identified in the medial portion of the posterior part of the right lobe of the liver where increased RBC accumulation is seen, it does not seem to be useful to proceed again to liver imaging with 99mTc-sulfur colloid.

Correspondence

We thank Dr Zakavi for his interest for our case report written in H J N M 2006; 9: 109-110. Our reply is as follows: a) Since the patient after the diagnostic scintiscans underwent an operation, it was proved beyond any doubt that the hemangioma was located in such a place as we describe in our case report. Due to the anterior projection of the two organs, namely the kidney and the liver, at the anterior liver scintiscan the lesion was projected through the kidney. b) The US test could not specify correctly the position of the lesion because of the depth and the limited number of tests performed. c) The posterior view of the liver was less indicative in showing the position of the hemangioma because the kidney stood in between. d) As is mentioned in our paper all three diagnostic scanning procedures performed, gave to the patient a cumulative dose of 4mSv. This dose is quite acceptable for identifying an hemangioma that could erupt in the abdominal cavity. e) Of course many liver hemangiomas can be diagnosed after the first specific scan. Our presentation was not intended to show such an easy diagnostic procedure.

Dr. Sabri Zinkirkeser, Gaziantep Universitesi Tip, Fakultesi Hastanesi, Nukleer Tip ABD, Gaziantep, Turkey, Tel: +90 (342) 360 60 60, E-mail: szinkirkeser@yahoo.com

References


Radiosynoviorthesis – indications, side effects

To the Editor: Related to the subject of radiosynoviorthesis (RSV) or radio-synovectomy and the papers and correspondence about this subject published recently in HJNM, we would like to add and discuss the following, that briefly represent according to our knowledge, the main points for applying this treatment today [1-3]: It has been more than 50 years since the first intra-articular administration of radiopharmaceuticals for therapeutic purposes was introduced. Since then, RSV has been a reliable, safe, easy-to-use, and low cost treatment for chronic, persistent/relapsing synovitis [4,5]. This technique aims at the destruction of the pathologic-hypertrophied synovial membrane, resulting in local remission of the inflammation and improvement of patient’s life. Particles labeled with β-emitting isotopes are injected (although a small amount of low energy gamma-emission within the energy range, that is easily detected by conventional gamma camera systems, could be an advantage since it could provide imaging of the treated joint) [4,5].

The injection of the radiopharmaceutical into the joint cavity results in phagocytosis of the radio-labeled molecules by the phagocytes of the synovial membrane. Irradiation at first decreases hyperaemia, although often a slight thickening of synovium occurs. Thrombotic occlusion of capillaries in the superficial synovial lining is striking. Within a few weeks to months, fibrosis of the synovial lining is formed [5]. Filtration and resorption of the synovial fluid are reduced [5]. The main radiopharmaceuticals used are: yttrium-90 (90Y)-citrate/silicate for radiosynoviorthesis of the knees, rhenium-186 (186Re)-sulphide for joints of intermediate size (hip, shoulder, elbow, etc) and erbium-169 (169Er)-citrate for small joints (interphalangeal, metacarpophalangeal, metatarsophalangeal) [5, 6]. During the last 15-20 years, new radiopharmaceuticals have been introduced in clinical practice such as dysprosium-165 (165Dy), holmium-166 (166Ho), samarium-153 (153Sm), rhenium-188 (188Re), lutetium-177 (177Lu), etc. [7-9].

Bibliography